These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
123 related articles for article (PubMed ID: 34702694)
1. Clinical outcomes of everolimus-eluting bioresorbable scaffolds or everolimus-eluting stents in patients with acute myocardial infarction: two-year results of the randomised ISAR-Absorb MI trial. Wiebe J; Byrne RA; Alfonso F; Maeng M; Bradaric C; Kretov E; Cuesta J; Kuna C; Ibrahim T; Rivero F; Heugl M; Christiansen EH; Joner M; Schunkert H; Laugwitz KL; Kastrati A; Cassese S EuroIntervention; 2022 Mar; 17(16):1348-1351. PubMed ID: 34702694 [No Abstract] [Full Text] [Related]
2. Angiographic and clinical outcomes of STEMI patients treated with bioresorbable or metallic everolimus-eluting stents: a pooled analysis of individual patient data. Cassese S; Katagiri Y; Byrne RA; Brugaletta S; Alfonso F; Räber L; Maeng M; Iñiguez A; Kretov E; Onuma Y; Joner M; Sabaté M; Laugwitz KL; Windecker S; Kastrati A; Serruys PW EuroIntervention; 2020 Mar; 15(16):1451-1457. PubMed ID: 30719976 [TBL] [Abstract][Full Text] [Related]
3. Clinical Outcomes Before and After Complete Everolimus-Eluting Bioresorbable Scaffold Resorption: Five-Year Follow-Up From the ABSORB III Trial. Kereiakes DJ; Ellis SG; Metzger DC; Caputo RP; Rizik DG; Teirstein PS; Litt MR; Kini A; Kabour A; Marx SO; Popma JJ; Tan SH; Ediebah DE; Simonton C; Stone GW; Circulation; 2019 Dec; 140(23):1895-1903. PubMed ID: 31553222 [TBL] [Abstract][Full Text] [Related]
4. Absorb bioresorbable vascular scaffold versus everolimus-eluting metallic stent in ST-segment elevation myocardial infarction: 1-year results of a propensity score matching comparison: the BVS-EXAMINATION Study (bioresorbable vascular scaffold-a clinical evaluation of everolimus eluting coronary stents in the treatment of patients with ST-segment elevation myocardial infarction). Brugaletta S; Gori T; Low AF; Tousek P; Pinar E; Gomez-Lara J; Scalone G; Schulz E; Chan MY; Kocka V; Hurtado J; Gomez-Hospital JA; Münzel T; Lee CH; Cequier A; Valdés M; Widimsky P; Serruys PW; Sabaté M JACC Cardiovasc Interv; 2015 Jan; 8(1 Pt B):189-197. PubMed ID: 25616924 [TBL] [Abstract][Full Text] [Related]
5. 1-Year Outcomes of Everolimus-Eluting Bioresorbable Scaffolds Versus Everolimus-Eluting Stents: A Propensity-Matched Comparison of the GHOST-EU and XIENCE V USA Registries. Tamburino C; Capranzano P; Gori T; Latib A; Lesiak M; Nef H; Caramanno G; Naber C; Mehilli J; Di Mario C; Sabaté M; Münzel T; Colombo A; Araszkiewicz A; Wiebe J; Geraci S; Jensen C; Mattesini A; Brugaletta S; Capodanno D JACC Cardiovasc Interv; 2016 Mar; 9(5):440-9. PubMed ID: 26875648 [TBL] [Abstract][Full Text] [Related]
11. Arterial healing following primary PCI using the Absorb everolimus-eluting bioresorbable vascular scaffold (Absorb BVS) versus the durable polymer everolimus-eluting metallic stent (XIENCE) in patients with acute ST-elevation myocardial infarction: rationale and design of the randomised TROFI II study. Räber L; Onuma Y; Brugaletta S; Garcia-Garcia HM; Backx B; Iñiguez A; Okkels Jensen L; Cequier-Fillat À; Pilgrim T; Christiansen EH; Hofma SH; Suttorp M; Serruys PW; Sabaté M; Windecker S EuroIntervention; 2016 Jul; 12(4):482-9. PubMed ID: 26342471 [TBL] [Abstract][Full Text] [Related]
12. Prospective, randomized trial of bioresorbable scaffolds vs. everolimus-eluting stents in patients undergoing coronary stenting for myocardial infarction: the Intracoronary Scaffold Assessment a Randomized evaluation of Absorb in Myocardial Infarction (ISAR-Absorb MI) trial. Byrne RA; Alfonso F; Schneider S; Maeng M; Wiebe J; Kretov E; Bradaric C; Rai H; Cuesta J; Rivero F; Hoppmann P; Schlichtenmaier J; Christiansen EH; Cassese S; Joner M; Schunkert H; Laugwitz KL; Kastrati A Eur Heart J; 2019 Jan; 40(2):167-176. PubMed ID: 30520980 [TBL] [Abstract][Full Text] [Related]
13. Randomised comparison of a bioresorbable everolimus-eluting scaffold with a metallic everolimus-eluting stent for ischaemic heart disease caused by de novo native coronary artery lesions: the 2-year clinical outcomes of the ABSORB II trial. Chevalier B; Onuma Y; van Boven AJ; Piek JJ; Sabaté M; Helqvist S; Baumbach A; Smits PC; Kumar R; Wasungu L; Serruys PW EuroIntervention; 2016 Oct; 12(9):1102-1107. PubMed ID: 27564310 [TBL] [Abstract][Full Text] [Related]
14. Economic Outcomes of Bioresorbable Vascular Scaffolds Versus Everolimus-Eluting Stents in Patients Undergoing Percutaneous Coronary Intervention: 1-Year Results From the ABSORB III Trial. Baron SJ; Lei Y; Chinnakondepalli K; Vilain K; Magnuson EA; Kereiakes DJ; Ellis SG; Stone GW; Cohen DJ; JACC Cardiovasc Interv; 2017 Apr; 10(8):774-782. PubMed ID: 28427593 [TBL] [Abstract][Full Text] [Related]
15. Three-Year Outcomes With the Absorb Bioresorbable Scaffold: Individual-Patient-Data Meta-Analysis From the ABSORB Randomized Trials. Ali ZA; Gao R; Kimura T; Onuma Y; Kereiakes DJ; Ellis SG; Chevalier B; Vu MT; Zhang Z; Simonton CA; Serruys PW; Stone GW Circulation; 2018 Jan; 137(5):464-479. PubMed ID: 29089314 [TBL] [Abstract][Full Text] [Related]